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7 TSchizophrenia is characterized by loss of brain volume, whichmay represent an ongoing pathophysiological pro-
cess. This loss of brain volumemay be explainedby reduced neuropil rather than neuronal loss, suggesting abnor-
mal synaptic plasticity and cortical microcircuitry. A possible mechanism is hypofunction of the NMDA-type of
glutamate receptor, which reduces the excitation of inhibitory GABAergic interneurons, resulting in a disinhibi-
tion of glutamatergic pyramidal neurons. Disinhibition of pyramidal cells may result in excessive stimulation by
glutamate, which in turn could cause neuronal damage or death through excitotoxicity.
In this study, GABA/creatine ratios, and glutamate, NAA, creatine and choline concentrations in the prefrontal and
parieto-occipital cortices were measured in 17 patients with schizophrenia and 23 healthy controls using proton
magnetic resonance spectroscopy at an ultra-highmagnetic ﬁeld strength of 7 T. Signiﬁcantly lower GABA/Cr ra-
tios were found in patients with schizophrenia in the prefrontal cortex as compared to healthy controls, with
GABA/Cr ratios inversely correlated with cognitive functioning in the patients. No signiﬁcant change in the
GABA/Cr ratio was found between patients and controls in the parieto-occipital cortex, nor were levels of gluta-
mate, NAA, creatine, and choline differed in patients and controls in the prefrontal and parieto-occipital cortices.
Our ﬁndings support a mechanism involving altered GABA levels distinguished from glutamate levels in theme-
dial prefrontal cortex in schizophrenia, particularly in high functioning patients. A (compensatory) role for GABA
through altered inhibitory neurotransmission in theprefrontal cortexmay be ongoing in (higher functioning) pa-
tients with schizophrenia.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Schizophrenia is characterized by loss of brain volume that is at least
in part progressive in nature, andwhichmay represent an ongoingpath-
ophysiological process (Hulshoff Pol et al., 2008). This loss of brain vol-
ume may be explained by reduced neuropil rather than neuronal loss,
suggesting abnormal synaptic plasticity and cortical microcircuitry
(Harrison, 1999). The mechanisms underlying brain volume loss in
schizophrenia are not known, although it has been suggested that the
glutamatergic system may be involved (Harrison and Weinberger,
2005). A recent cross-sectional study showed that increased hippocam-
pal glutamatergic levels in unmedicated schizophrenia patients were
correlated with hippocampal volume reductions (Kraguljac et al.,ry, Internal address A.01.126,
3508 GA, The Netherlands.
@jhmi.edu (A. Marsman).
f Medicine, Russell H. Morgan
Wolfe St. Park 359, Baltimore,
. This is an open access article under2013). Glutamate (Glu) is themost abundant excitatory neurotransmit-
ter in the central nervous system (CNS) (Fonnum, 1984). Recent meta-
analyses of cross-sectional studies show that glutamate levels are
decreased in chronic schizophrenia patients and elevated in medication-
naïve and medication free patients (Marsman et al., 2013a; Poels et al.,
2014). It may thus be that glutamate is elevated in the early stages of
schizophrenia and decreases after treatment with antipsychotic medica-
tion. Indeed, pharmacologically induced NMDA receptor hypofunction
causes increases in glutamate levels (Moghaddam et al., 1997). Also, a
longitudinal study (De la Fuente-Sandoval et al., 2013) and a cross-
sectional study (Kegeles et al., 2012) showed that antipsychotic medica-
tion decreases the elevated glutamate levels in the unmedicated state. Al-
tered glutamate levelsmay be a result of hypofunction of the NMDA-type
of glutamate receptor (Olney et al., 1999; Kondziella et al., 2007; Stone
et al., 2009). NMDA-receptor hypofunction reduces the excitation of in-
hibitory GABAergic interneurons, resulting in a disinhibition of gluta-
matergic pyramidal neurons, which may drive a hyperdopaminergic
state that produces psychosis. A major effect of NMDA receptor antago-
nism may be to produce disinhibition of pyramidal cells (Lisman et al.,
2008; Lewis and Moghaddam, 2006). Disinhibition of pyramidal cellsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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cause neuronal damage or death through excitotoxicity. One of the
meta-analyses showed an increase in glutamine, the precursor of gluta-
mate, in schizophrenia, which may lead to increased glutamate levels as
reported in medication-naïve and medication free patients (Marsman
et al., 2013a; Poels et al., 2014). However, in case of decreased glutamate
as seen in chronic patients, it could also suggest a deﬁciency in glutamin-
ase, the enzyme that converts glutamine into glutamate (Marsman et al.,
2013a).
GABA has indeed been implicated in schizophrenia based on post-
mortem and animal studies showing reduced expression of pre- and
postsynaptic markers of GABAergic neurotransmission in subpopula-
tions of GABAergic interneurons in the prefrontal cortex in postmortem
and animal studies (Benes and Berretta, 2001; Lewis et al., 2004; Coyle,
2004). However, postmortem studies generally include patients who
have been ill for many years. To examine glutamate and GABA levels
in the early stages of the disease, in vivomeasurements using magnetic
resonance spectroscopy (MRS) are the method of choice (De la Fuente-
Sandoval et al., 2011; Goto et al., 2009).
So far, a total of seven studies investigated GABA levels in vivo in the
brains of patients with schizophrenia, using protonMRS (1H -) (Kegeles
et al., 2012; De la Fuente-Sandoval et al., 2011; Goto et al., 2009; Ongür
et al., 2010; Tayoshi et al., 2010; Yoon et al., 2010; Rowland et al., 2013),
which reported increased (Kegeles et al., 2012; Ongür et al., 2010), de-
creased (Goto et al., 2009; Yoon et al., 2010), and normal (Kegeles
et al., 2012; Goto et al., 2009; Tayoshi et al., 2010; Yoon et al., 2010;
Rowland et al., 2013) GABA levels dependent on disease stage, medica-
tion intake and brain area studied. The only study of GABA in unmedi-
cated patients found elevated GABA levels in the medial prefrontal
cortex in unmedicated patients, but not in medicated patients, suggest-
ing that antipsychotic medication decreases the elevated GABA levels
(Kegeles et al., 2012). However, since these studies have been done at
conventional magnetic ﬁeld strengths (such as 3 T) subtle changes in
these metabolite levels may have remained concealed.
Performing 1H-MRS at ultra-high magnetic ﬁeld strength (7 T) has
two clear advantages. The sensitivity of the measurements of metabo-
lite concentrations is increased because of the increased signal-to-
noise ratio (SNR) and the increased spectral resolution allows for a bet-
ter separation of the individual metabolite spectra. For instance, at a
magnetic ﬁeld strength of 7 T it is now possible to adequately separate
the glutamate and glutamine signals resulting in a higher accuracy of
glutamate measurement (Tkác et al., 2001). However, detection of me-
tabolites at a highermagneticﬁeld strength is complicated by reduced ac-
curacy in localization of the region of interest (Boer et al., 2011;
Andreychenko et al., 2012). The sLASER (semi-localized by adiabatic se-
lective refocusing) sequence enables 1H-MRS of the human brain at 7 T
with increased localization accuracy, SNR and reliability (Boer et al.,
2011; Marsman et al., submitted). Despite the increased SNR, the mea-
surement of GABA is not straightforward because the concentration of
GABA is low compared to other brain metabolites and the GABA signal
is obscured by other overlappingmetaboliteswith higher signal intensity.
To overcome this problem, spectral editing techniques can be applied to
isolate the GABA signal (Puts and Edden, 2012). In this study we used
the sLASER sequence combined with editing techniques (MEGA-sLASER)
which allows for accurate and time-efﬁcient detection of GABA
(Andreychenko et al., 2012).
The purpose of this studywas tomeasureGABA and glutamate levels
in patients with schizophrenia and healthy control subjects at ultra-
high ﬁeld (7 T). We collected data from the medial prefrontal region,
which is known to show structural abnormalities in schizophrenia
(Harrison, 1999), and the medial parieto-occipital region as a control
area. Based on prior MRS studies of medicated schizophrenia patients,
and structural MRI studies of schizophrenia patients which suggest
alterations in the frontal brain region and only to a limited extent in
the occipital brain region (Harrison, 1999; Haijma et al., 2013), we hy-
pothesized that frontal GABA and glutamate levels are reduced, andparieto-occipital GABA and glutamate levels are unchanged in schizo-
phrenia (Goto et al., 2009; Ongür et al., 2010; Yoon et al., 2010). To
our knowledge this is the ﬁrst study in schizophrenia patients using
1H-MRS at a magnetic ﬁeld strength of 7 T.
2. Methods
2.1. Subjects
A total of 40 individuals participated in the study, including 17 pa-
tients with schizophrenia, and 23 healthy control participants matched
to the patients for age, sex and their parents3 socio-economic status.
Healthy participants had no major psychiatric or neurological history,
no history of drug or alcohol abuse, and no ﬁrst-degree relatives with
psychiatric or neurological disorders. The study was approved by the
Medical Ethics Committee of the University Medical Center Utrecht,
The Netherlands, and performed according to the directives of the Dec-
laration of Helsinki (amendment of Seoul, 2008). All participants pro-
vided written informed consent prior to the examination.
All individuals underwent psychiatric assessment using the Compre-
hensive Assessment of Symptoms and History (Andreasen et al., 1992).
Symptom severity was assessed using the Positive and Negative Syn-
drome Scale (PANSS) (Kay et al., 1987). Current daily dosage and cu-
mulative life-time dosage of antipsychotic medication in haloperidol
equivalents were calculated (Andreasen et al., 2010). In addition, cur-
rent or prior use of benzodiazepines was established. All individuals
underwent a general cognitive assessment using the full Wechsler
Adult Intelligence Scale (WAIS)— III (Wechsler, 1997), which revealed
a total intelligence quotient (TIQ) as well as a verbal and performance
IQ, andworkingmemory, perceptual reasoning, and verbal comprehen-
sion indices. Cognitive assessment could be successfully completed in
all but three healthy subjects because of logistical reasons. One patient
was not able to complete the MR acquisition because of a relapse in
symptoms.
No differences between the groups were found for age, parental
completed level of education and sex. Groups differed signiﬁcantly in
completed level of education, with patients having lower education,
and on general cognitive functioning, with patients having a lower
level of intelligence, as compared to the controls (Table 1).
2.2. MR acquisition
All investigations were performed on a 7 T whole body MR scanner
(Philips, Cleveland, OH, USA). A birdcage transmit head coil was used
in dual transmit driven by 2 × 4 kW ampliﬁers, in combination with a
32-channel receive coil (both Nova Medical, Inc., Burlington, MA, USA).
MR acquisition took approximately 50 min per participant.
For anatomical reference and gray andwhitematter tissue classiﬁca-
tion a T1-weighted magnetization prepared rapid gradient echo (MP-
RAGE) sequence was obtained (450 slices, slice thickness = 0.8 mm,
TR = 7 ms, TE = 3 ms, ﬂip angle = 8°, FOV = 250 × 200 × 180 mm,
312 × 312 acquisition matrix, SENSE factor 2.7, scan duration = 408 s).
For the assessment of glutamate and themajor spectral components
NAA, creatine and choline, 1H-MRS experiments were conducted using
a sLASER sequence (semi-localized by adiabatic selective refocusing;
TE = 28 ms, 32 averages, TR = 5 s, acquisition time = 2 min 40 s,
4 kHz acquisition bandwidth, 2048 datapoints) (Fig. 1). Voxels
(2 × 2 × 2 cm3) were located in the medial prefrontal and medial
parieto-occipital lobes (Fig. 2). Non-water-suppressed spectra were ob-
tained for quantiﬁcation (carrier frequencywas set to the chemical shift
of H2O, acquisition time = 10 s).
GABA-edited 1H-MRS experiments were conducted using a MEGA-
sLASER sequence (TE = 74 ms, 64 averages, TR = 4 s, acquisition
time = 4 min 16 s, 4 kHz acquisition bandwidth, 2048 datapoints)
(Fig. 1). Voxels (2.5 × 2.5 × 2.5 cm3) were located in the medial frontal
and medial parieto-occipital regions (Fig. 2). GABA-editing with
Table 1
Demographic characteristics.
Characteristic Patients Controls Statistic (p-value based on t, χ2)
Sex, M/F, N 13/4 16/7 0.45
Age, mean (SD), min–max, years 27.6 (6.1), 20.6–41. 7 27.7 (5.3), 21.5–40. 9 0.97
Years of education, mean (SD)
Participants 13.3 (1.9) 14.1 (2.1) 0.08
Parents 14.3 (3.0) 15.0 (1.3) 0.61
Total IQ, mean (SD) 92.8 (14.5) 108.3 (13.0) 0.002
Duration of illness, mean (SD), min–max, months 77.4 (82.1), 1–213
PANSS, mean (SD)
Total 53.1 (12.7)
Negative 12.9 (4.5)
Positive 12.7 (5.1)
General 27.5 (7.3)
Antipsychotic medication
Current daily dosage in haloperidol equivalentsa, N, mean (SD)
Typical
Clozapine 7, 4.26 (2.15)
Atypical 14, 5.48 (2.92)
Olanzapine 8, 6.84 (2.79)
Risperidone 1, 5.56
Aripiprazole 4, 4.04 (1.41)
Sulpiride 1, 0.29
Antipsychotic medication
Cumulative dosage in haloperidol equivalentsb, N, mean (SD)
Typical 5, 572 (483)
Clozapine 8, 6031 (6846)
Atypical 16, 3903 (4003)
Olanzapine 15, 2647 (3904)
Risperidone 5, 1934 (3219)
Aripiprazole 7, 1590 (1418)
Quetiapine 4, 445 (638)
Benzodiazepines current N (%), cumulative N (%) 6 (35%), 11 (65%)
The signiﬁcance of bold values indicates level was set at 0.05.
a 4 patients were using two or more types of antipsychotic medication at the time of the study.
b 13 patients had used two or more types of antipsychotic medication during their lifespan.
Fig. 1. Typical metabolite spectra and ﬁts.
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pulse between 1.9 (edit-on) and 1.4 ppm (edit-off) in subsequent
scans (Andreychenko et al., 2012). After frequency and phase alignment
the subtraction of edit-on and edit-off scans yielded a GABA spectrum
where the summation of all scans resulted in a non-edited spec-
trum which was used for the determination of the creatine peak
(Andreychenko et al., 2012). Prior to the MRS exams, second order B0
shimming was applied using the FASTERMAP algorithm at the voxel
of interest (Gruetter, 1993; Gruetter and Boesch, 1992). Second, at
this location, a high B1 ﬁeld was generated to minimize chemical shift
displacement artifacts (Versluis et al., 2010). The highest possible B1
ﬁeld was generated by optimizing the phase of both transmit channels
to locally assure constructive B1 interferences (Boer et al., 2011).
Spectral qualitymeasures, i.e. signal-to-noise ratio (SNR), Cramèr–Rao
lower bounds (CRLBs) of the major spectral components, and linewidth,
were calculated and addressed for differences between groups and
voxel locations. The SNR of the MEGA-sLASER was even higher than re-
ported in the initial paper for this sequence, which also showed standard
deviations of only 7% for GABA/Cr ratios (Andreychenko et al., 2012).
Small signiﬁcant differences between groups were found for SNR of theFig. 2.Voxel placement. A:Medial prefrontal sLASER voxel: (A) sagittal view, (B) axial view, and
and (F) coronal view.Medial parieto-occipital sLASER voxel: (G) sagittal view, (H) axial view, an
view, and (L) coronal view.frontal sLASER spectra, linewidth of the parieto-occipital spectra and
CRLB of frontal NAA (Table 2). High SNRs, lowCRLBs and small linewidths
were found, hence overall quality of the obtained spectra can be regarded
as excellent.
2.3. Spectral ﬁtting and quantiﬁcation
Retrospective phase and frequency alignment was performed on all
data sets of each measurement (Waddell et al., 2007). Fitting of the
sLASER spectra was performed with LCModel-based software imple-
mented in Matlab (De Graaf, 1999), which uses a priori knowledge of
the spectral components to ﬁt metabolite resonances (Govindaraju
et al., 2000). A ﬁfth-order polynomial baseline was used. The follow-
ing 16 metabolites and a measured macromolecular baseline (Behar
et al., 1994) were ﬁtted to the spectra: acetate, aspartate, choline
(Cho), phosphorylcholine (PC), glycerophosphorylcholine (GPC),
phosphorylethanolamine (PE), creatine (Cr), phosphocreatine (PCr),
N-acetyl aspartate (NAA), N-acetyl aspartyl glutamate (NAAG), GABA,
Glu, glutamine (Gln), glutathione (GSH), myo-inositol (mIns), and
taurine (Tau). Levels of Glu, total NAA (NAA + NAAG), total creatine(C) coronal view.Medial prefrontalMEGA-sLASER voxel: (D) sagittal view, (E) axial view,
d (I) coronal view.Medial parieto-occipital MEGA-sLASER voxel: (J) sagittal view, (K) axial
402 A. Marsman et al. / NeuroImage: Clinical 6 (2014) 398–407(Cr + PCr) and total choline (Cho + PC + GPC + PE) were estimated
using the water signal as an internal reference and calculated as follows
(Gasparovic et al., 2009):
½met ¼
 
signalmet
signalwater
ðvolGM½waterGM þvolWM½waterWM þvolCSF½waterpure Þ
volGMþvolWM
!
where [met] is the metabolite concentration, signalmet is the ﬁtted
signal intensity of themetabolite, accounting for the number of protons,
and signalwater is the ﬁtted signal intensity of water, accounting for the
number of protons; volGM, volWM and volCSF are respectively the
gray matter fraction, white matter fraction and cerebrospinal ﬂuid
(CSF) fraction in the voxel; and [waterGM], [waterWM], and [waterpure]
are respectively the water concentration in gray matter, white matter
or CSF. For determining the contribution of gray matter, white matter
and CSF of each voxel, the software package SPM8was used to segment
the T1-weighted image. In the T1-weighted image, the position of the
1H-MRS voxel was determined, after which the amount of gray matter,
white matter and CSF in the 1H-MRS voxel was computed. To account
for differences in transverse relaxation between water and metabolites,
a correction was applied based on reported T2 values at 7 T of 47 ms on
average for water and 107 ms assumed for the metabolites (Marjańska
et al., 2012). Statistical analysis of the gray andwhitematter fractions in
the frontal and parieto-occipital MEGA-sLASER (GABA/Cr) and sLASER
(glutamate, NAA, creatine, choline) revealed correlations N0.95 for
both gray and white matter fractions in the two voxels.
Fitting of the MEGA-sLASER spectra was performed by frequency-
domain ﬁtting of the GABA and creatine resonances to a Lorentzian
line-shape function in Matlab. GABA levels were expressed as the ratios
of their peak areas relative to the peak areas of the creatine resonance.
Because of poor quality of the T1-weighted MP-RAGE sequence, in
two healthy subjects the gray and white matter separation could not
be estimated reliably in the frontal cortex, and in two healthy subjects
the parieto-occipital cortex. For analyses with correction for gray and
white matter fractions these subjects were not included in the analyses.
Because of poor spectral quality as established by a Cramér–Rao
lower bound (CRLB) of more than 20% and visual inspection, some
datawere excluded from the study. Frontal sLASER spectrawere exclud-
ed for three healthy controls and two patients; parieto-occipital sLASER
spectra were excluded for three healthy subjects and one patient; fron-
tal MEGA-sLASER spectra were excluded for four healthy subjects and
three patients; and parieto-occipital MEGA-sLASER spectra were ex-
cluded for four healthy subjects and one patient. Spectra were mainly
excluded because of poor shimming or technical issues. CRLBs of Glu,
NAA, Cr and Cho never exceeded 20% and CRLBs of GABA/Cr exceeded
20% in only two instances.
Thus, frontal MRS results are based on 18 healthy subjects and 14 pa-
tients and parieto-occipital MRS results are based on 17 healthy subjects
and 15 patients. Frontal GABA-editedMRS results are based on 19healthy
subjects and 13 patients and parieto-occipital GABA-edited MRS results
are based on 19 healthy subjects and 15 patients.Table 2
Spectral quality (mean (SD)).
Medial prefrontal cortex
Patients Controls Statistic (p-value based o
SNR sLASERa 51.9 (15.2) 64.8 (19.7) 0.046
SNR MEGA-sLASERa 9.0 (3.2) 11.5 (5.2) n.s.
Linewidth (Hz) 9.0 (1.2) 8.4 (1.4) n.s.
CRLB (%) GABA/Cr 3.6 (1.0) 3.1 (1.6) n.s.
CRLB (%) Glu 2.7 (0.8) 2.2 (0.9) n.s.
CRLB (%) NAA 2.3 (0.6) 1.8 (0.7) 0.049
CRLB (%) Cr 1.2 (0.3) 1.0 (0.3) n.s.
CRLB (%) Cho 2.0 (0.6) 1.7 (0.5) n.s.
The signiﬁcance of bold values indicates level was set at 0.05.
a Signal-to-noise ratios are based on non-apodized spectra.2.4. Statistical analysis
Statistical analyses were performed using SPSS 21.0 (2012, Chicago,
IL). Demographic characteristics were addressed for differences between
the groups using Student3s t-tests and χ2-tests. Data were checked for
normality of their distributions. No transformations were required on
any of the data. Multiple univariate analyses of variance were done with
metabolite level as dependent variable and with group (schizophrenia
patients, healthy controls), age, sex and gray and white matter fractions
in the voxel as independent variables. In the case of a main signiﬁcant ef-
fect for group, age-by-group, sex-by-group, intelligence, and intelligence-
by-groupwere added separately to themodel to assess interaction effects.
In patients, possible dependencies of metabolite concentrations
depended on clinical symptomatology, or on current and cumulative an-
tipsychoticmedication intakeweremeasured through post-hoc analyses.3. Results
3.1. GABA
A signiﬁcantmain effect of group on the GABA/Cr ratio was found in
the medial prefrontal cortex (F(1,24) = 7.33, p = 0.012), with the pa-
tients having lower GABA/Cr ratios as compared to the healthy controls
(Table 3; Fig. 3A). This effect remained signiﬁcant when corrections for
gray and white matter fractions were removed from the analyses (thus
adding the GABA/Cr ratio data from an additional two healthy subjects,
with F(1,28)=4.91, p=0.035). Therewere no signiﬁcant effects of age
or age-by-group interaction on the GABA/Cr ratio in the prefrontal
cortex.
GABA/Cr ratio did not reveal signiﬁcant differences betweenpatients
and controls in the parieto-occipital cortex (F(1,24) = 2.35, p = n.s.)
(Fig. 3B). A signiﬁcant main effect of age on the GABA/Cr ratio in the
parieto-occipital cortex was found (F(1,24) = 7.88, p = 0.01), with
older individuals having lower ratios, irrespective of disease.
In the parieto-occipital cortex a signiﬁcant correlation was
found between the GABA/Cr ratio and glutamate level in controls
(r(10)=−0.56, p=0.03), with higher GABA/Cr ratios being associated
with lower levels of glutamate, an association not reaching signiﬁcance
inpatients (r(9) =−0.25, p = n.s.).
There were no signiﬁcant effects for sex on GABA/Cr ratios in the
frontal and parieto-occipital cortices.3.2. Glutamate
In themedial prefrontal cortex thesewasno signiﬁcantmain effect of
group on glutamate level (F(1,26) = 0.97, p = n.s.) (Table 3; Fig. 3C).
There were signiﬁcant main effects of age and sex on glutamate levels,
with older individuals having lower levels than younger individuals
(F(1,26) = 11.16, p = 0.003), and with higher glutamate levels inMedial parieto-occipital cortex
n t, χ2) Patients Controls Statistic (p-value based on t, χ2)
50.5 (12.9) 61.0 (22.8) n.s.
10.7 (4.0) 9.0 (3.4) n.s.
9.5 (1.1)a 8.5 (0.9) 0.009
3.2 (1.8) 3.5 (1.6) n.s.
2.8 (1.1) 2.7 (1.6) n.s.
2.2 (1.0) 1.9 (0.8) n.s.
1.3 (0.5) 1.3 (0.6) n.s.
3.2 (1.4) 3.4 (2.8) n.s.
Table 3
Metabolite levels and gray and white matter fractions (mean (SD))a.
Medial prefrontal cortex Medial parieto-occipital cortex
Patients Controls Statistic (F, p) Patients Controls Statistic (F, p)
GABA/Cr ratio 0.12 (0.02) 0.14 (0.03) 7.33, 0.012 0.15 (0.04) 0.14 (0.03) 2.59, n.s.
Glutamate (mM) 8.48 (1.34) 8.65 (1.14) 0.97, n.s. 8.45 (1.07) 8.48 (1.26) 0.00, n.s.
NAA (mM) 9.36 (1.23) 9.85 (1.39) 1.04, n.s. 10.35 (1.26) 10.85 (1.13) 2.67, n.s.
Creatine (mM) 8.35 (1.45) 8.26 (1.43) 0.08, n.s. 8.48 (1.24) 8.28 (1.25) 0.13, n.s.
Choline (mM) 5.02 (1.96) 5.14 (1.51) 0.49, n.s. 3.48 (1.12) 3.35 (1.23) 0.00, n.s.
GM (%) sLASER 72.1 (10.3) 71.4 (13.6) 0.47, n.s. 72.1 (7.4) 70.1 (12.1) 1.79, n.s.
WM (%) sLASER 12.9 (8.8) 19.5 (14.9) 2.29, n.s. 22.1 (6.8) 25.2 (13.9) 4.37, n.s.
GM (%) MEGA-sLASER 68.4 (9.5) 68.1 (10.8) 0.06, n.s. 69.2 (7.8) 68.0 (10.4) 0.06, n.s.
WM (%) MEGA-sLASER 18.5 (7.0) 24.0 (11.2) 1.46, n.s. 24.5 (7.4) 27.7 (12.2) 1.20, n.s.
The signiﬁcance of bold values indicates level was set at 0.05.
a Data are based on two separate 1H-MRS measurements each done in two brain areas (prefrontal and parieto-occipital). A MEGA-sLASER sequence was performed for assessment of
GABA/Cr ratios and successfully completed in 13 patients and 19 controls in themedial prefrontal cortex and in 15 patients and 19 controls in themedial parieto-occipital cortex. A sLASER
sequence was performed for assessment of glutamate, NAA, creatine, and choline levels (corrected for gray and white matter fractions in the voxel) and successfully completed in 14 pa-
tients and 18 controls in the medial prefrontal cortex and in 15 patients and 17 controls in the medial parieto-occipital cortex.
403A. Marsman et al. / NeuroImage: Clinical 6 (2014) 398–407females as compared to males (F(1,26) = 4.64, p = 0.04), irrespec-
tive of disease.
Glutamate did not show any signiﬁcant effects for group, age, and
sex on glutamate level in the parieto-occipital cortex (Fig. 3D).Fig. 3.GABA/Cr ratios and glutamate concentrations in healthy controls and patients with schiz
show signiﬁcantly lowermedial prefrontal GABA/Cr ratios as compared to healthy controls (F(1
(B) There is no signiﬁcant difference in medial parieto-occipital GABA/Cr ratio between patien
prefrontal glutamate concentration between patients and controls (F(1,26) = 0.97, p = n.s.).
between patients and controls (F(1,26) = 0.002, p = n.s.).3.3. Other metabolites
No signiﬁcantﬁndingswere revealed for any of the othermetabolites,
except for signiﬁcant effects of age on prefrontal NAA levels (F(1,26) =ophrenia. The blue (controls) and red (patients) bars indicate group averages. (A) Patients
,24)= 7.33, p= 0.012), when correcting for age, sex, and gray andwhitematter fractions.
ts and controls (F(1,24) = 2.35, p = n.s.). (C) There is no signiﬁcant difference in medial
(D) There is no signiﬁcant difference in medial parieto-occipital glutamate concentration
404 A. Marsman et al. / NeuroImage: Clinical 6 (2014) 398–4077.22, p=0.01) and prefrontal creatine levels (F(1,26)=5.21, p= 0.03),
with lower levels being found in older individuals, irrespective of dis-
ease; and for a signiﬁcant effect of sex on parieto-occipital NAA levels
with higher levels in females than in males (F(1,26) = 6.18, p = 0.02),
irrespective of disease.
3.4. Associations with intelligence
GABA/Cr ratio showed a signiﬁcant interaction effect of intelligence-
by-group in the prefrontal cortex (F(1,20) = 4.77, p = 0.04), when in-
telligence and intelligence-by-group interaction were added to the
model. This effect remained signiﬁcant when corrections for gray and
white matter fractions were removed from the analyses (adding the
GABA/Cr ratio data from an additional one healthy subject) with
F(1,23) = 4.79, p = 0.039. This interaction effect was due to pa-
tients with a higher intelligence level having a lower GABA/Cr ratio
(r=−0.92, p b 0.001) (Fig. 4), whereas in healthy individuals no signif-
icant association between intelligence level and GABA/Cr was found. In
patients, the correlation between higher level of intelligence and lower
GABA/Cr ratio was found for all aspects of intelligence but was most
prominently reﬂected in performance IQ (r=−0.89, p b 0.001), followed
by working memory index (r =−0.76, p = 0.02), verbal IQ (r =−0.74,
p= 0.02), perceptual reasoning index (r=−0.72, p= 0.03), and verbal
comprehension index (r =−0.70, p = 0.04).
3.5. Associations with symptomatology, medication intake and substance
use
Post-hoc analyses revealed that parieto-occipital glutamate
(r =−0.85, p = 0.003), parieto-occipital NAA (r =−0.84, p = 0.005),
and parieto-occipital choline (r =−0.79, p = 0.012) levels were nega-
tively correlated with the severity of negative symptoms.
No signiﬁcant associations between any of the metabolite levels in
the prefrontal and parieto-occipital cortices with current or cumulative
dosage of classical or atypical antipsychotic medication were found.
Also, no signiﬁcant associations were found between metabolite levels
and benzodiazepine use.
Smoking status, alcohol use in the past month, and cannabis use in
the past month could be retrieved in 34 individuals (85%). 7 (41%) pa-
tients and 2 (9%) healthy subjects were smokers. Smoking did not
alter the ﬁndings when added as a covariate to the signiﬁcant analyses.
7 (41%) patients and 13 (57%) healthy subjects consumed alcohol in the
past month. Alcohol use did not alter the signiﬁcant ﬁndings whenFig. 4. Medial prefrontal GABA/Cr ratios in patients with schizophrenia signiﬁcantly
decrease with increasing total IQ, when correcting for age, sex, and gray and white matter
fractions. (r =−0.91, p = 0.001).added to the analyses as a covariate. Cannabis was used in the past
month by 2 (9%) patients and were not used by any of the healthy sub-
jects. Cannabis use did not alter the ﬁndings when added as a covariate
in the signiﬁcant analyses.
4. Discussion
To our knowledge, this study presents the ﬁrst proton magnetic reso-
nance spectroscopy (MRS) measurements of GABA and glutamate levels
in vivo in the brains of patients with schizophrenia at a magnetic ﬁeld
strength of 7 T. The main ﬁnding is a signiﬁcantly lower GABA/Cr ratio
in the prefrontal cortex in patients with schizophrenia as compared to
healthy controls. In addition, the lowerprefrontal GABA/Cr ratioswere as-
sociated with higher levels of general cognitive functioning in the pa-
tients. No signiﬁcant difference in the GABA/Cr ratio was found
between patients and controls in the parieto-occipital cortex. Also, no sig-
niﬁcant differences in glutamate, NAA, creatine, and choline, were found
in patients and controls in the prefrontal and parieto-occipital cortices.
The main ﬁnding of this study is a signiﬁcantly lower GABA/Cr ratio
in the prefrontal cortex in patients as compared to healthy controls
based on a GABA dedicated MRS sequence operating at 7 T. Our ﬁnding
is consistent with postmortem studies in schizophrenia, suggesting
diminished GABA production based on decreased levels of mRNA
encoding for GAD67 (Olney et al., 1999; Kondziella et al., 2007; Stone
et al., 2009; Lisman et al., 2008)— the enzyme that facilitates GABA syn-
thesis from glutamate, decreased levels of mRNA encoding for GAT-1
(De la Fuente-Sandoval et al., 2011; Goto et al., 2009) – the transporter
that removes GABA from the synaptic cleft – and increased expression
of theα2 subunits of the GABAA receptor— the major inhibitory recep-
tor in the brain mediating most of the physiological actions of GABA
(Sieghart et al., 1999). Moreover, the ﬁnding of lower GABA/Cr ratios in
patients agrees with the hypothesis that NMDA-receptor hypofunction
reduces the excitation of GABAergic interneurons (Kondziella et al.,
2007; Stone et al., 2009). However, we found an inverse correlation be-
tween GABA/Cr ratios and glutamate levels in the parieto-occipital cortex
in healthy controls but not in patients. Considering the tight coupling of
GABA and glutamate through GAD, this is unexpected and contrasts
with previous studies reporting positive correlations between GABA and
glutamate in patients in the anterior cingulate and parieto-occipital corti-
ces (Ongür et al., 2010) and in a mixed sample of patients and healthy
controls in the prefrontal cortex (Kegeles et al., 2012).
Interestingly, we ﬁnd the decrease in GABA/Cr ratios in patientswith
schizophrenia to be associated with a higher level of general cognitive
functioning. In patients, the association between higher general level
of intelligence and lower GABA/Cr ratio was found for all aspects of in-
telligence. Since we ﬁnd an association between GABA and intelligence
in the patients and not in the healthy controls, it could reﬂect a compen-
satory mechanism to (continue) functioning at an (above) average
level. When separated out for several aspects of IQ, the decreased
GABA/Cr ratio in patients was associatedwith performance IQ, followed
by higher workingmemory functioning, perceptual reasoning, and ver-
bal comprehension (all≥0.70). The medial prefrontal cortex serves as a
hub in (performance) IQ as part of the brain3s functional network (Van
den Heuvel et al., 2009). Moreover, this brain area revealed disruption
of brain connectivity in schizophrenia, as one of the brain3s hub areas
potentially leading to a reduced communication capacity and altered
functional brain dynamics (Van den Heuvel et al., 2013). As observed
in many earlier studies, we also found a lower intelligence level in pa-
tients with schizophrenia, which possibly exists prior to the disease
onset (Hedman et al., 2013) and is associated with genetic risk for
schizophrenia (Toulopoulou et al., 2007), thus conﬁrming contributions
from the medial prefrontal cortex to both schizophrenia and intelli-
gence. However, the inverse correlation between GABA and intelligence
contrasts with ﬁndings that GABA deﬁcits occur as part of the impair-
ment of schizophrenia (Enomoto et al., 2011; Menzies et al., 2007). An
alternative explanation might be that patients with a higher IQ are
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greater extent. Although there were no correlations found between
GABA/Cr ratios andmedication intake in this study, a previous study re-
ports an inverse correlation between GABA levels and antipsychotic
medication intake (Tayoshi et al., 2010).
We found no signiﬁcant changes in glutamate levels in patients with
schizophrenia as compared to healthy controls based on 1H-MRS at 7 T.
This is consistent with a recent large study in which no changes in glu-
tamate levels were found in schizophrenia (Bustillo et al., 2014). A re-
cent meta-analysis showed an overall reduction of frontal glutamate
levels in patients as compared to healthy controls (Fonnum, 1984).
However, in that study it was also suggested that glutamate levels are
increased in the early stage of the disease and begin to decrease below
control levels around the age of 25 years when most patients have
been ill for a few years. Moreover, another meta-analysis suggested
that glutamatergic levels are elevated in medication-naïve and medica-
tion free patients (Poels et al., 2014). Since the average age of the schizo-
phrenia patients in this study is 27.6 years with an average illness
duration of 77 months (Table 2), it is possible that glutamate levels in
these patients are approaching control levels because of their disease
stage. Other levels of brain metabolites, including those of prefrontal
and parieto-occipital NAA, a marker of neuronal integrity, and of crea-
tine, a marker of energy metabolism, did not differ signiﬁcantly be-
tween patients and healthy controls. Although meta-analyses showed
reduced NAA levels in patients with schizophrenia in the frontal lobe
(Steen et al., 2005), most of the studies that were included in these
meta-analyses were in patients who had been ill for many years
(Hulshoff Pol and Kahn, 2008; Harrison, 1999; Steen et al., 2005;
Brugger et al., 2011; Kraguljac et al., 2012). We did ﬁnd that parieto-
occipital glutamate, NAA and choline were negatively correlated with
negative symptom severity. An inverse relationship between negative
symptoms and NAA has been reported before (Brugger et al., 2011).
The correlation between glutamate and negative symptoms agrees
with previous ﬁndings of correlations between negative symptoms and
measures of abnormal glutamatergic neurotransmission (Pilowsky et al.,
2006; Szulc et al., 2005). Moreover, NAA and glutamatergic neurotrans-
mission are probably closely related (Reynolds and Harte, 2007).
Antipsychotic medication may alter metabolite levels in the brain
(McLoughlin et al., 2009); including reductions in GABA and Glx (the
sum of glutamate and glutamine) levels in the medial prefrontal cortex
(Kegeles et al., 2012). However, antipsychotic use andmetabolite levels
did not reveal signiﬁcant associations in our study. The intake of benzo-
diazepines may increase GABA levels, since benzodiazepines are GABAA
receptor agonists (Sieghart and Sperk, 2002) (but see Goddard et al.,
2004 for a decrease in GABA levels by down-modulation of GAD func-
tion and gene expression). Two-thirds of the patients had used benzodi-
azepines since they had become ill and one-third of the patients were
currently taking benzodiazepines. However, we found no signiﬁcant
associationswith cumulative or current intake, althoughwe did observe
that patients that were currently taking benzodiazepines had (non-
signiﬁcantly) higher GABA/Cr ratios compared to those who did
not. Thus, it seems unlikely that medication intake explained our ﬁnd-
ing of decreased GABA/Cr ratio in the frontal cortex in patients. This is
however in contrast with a previous study which found a negative cor-
relation between frontal GABA and antipsychotic medication intake
(Tayoshi et al., 2010).
Irrespective of disease and with increasing age, we ﬁnd signiﬁcantly
lower parieto-occipital GABA and prefrontal glutamate, NAA and crea-
tine levels in the current 7 T 1H-MRS study. Parieto-occipital but not
frontal GABA levels decreased with increasing age in these relatively
young adult individuals, whereas for all the other metabolites the fron-
tal but not parieto-occipital levels were lower with older age. Possibly
high levels of the inhibitory neurotransmitter GABA are still important
for development and plasticity of the prefrontal cortex in young adult-
hood (Ben-Ari et al., 2007). Decreases in glutamate level with age are
consistent with previous studies (Marsman et al., 2013a;2013b) andmay be associated with age-dependent neuronal pruning (Marsman
et al., 2013b; Segovia et al., 2001). Lower NAA levels with increasing
age have been reported before (Angelie et al., 2001; Raininko and
Mattsson, 2010; Sailasuta et al., 2008) and may reﬂect a reduction of
brain volume (Raininko and Mattsson, 2010) or neuronal function. A
lower creatine level with increasing age may be a sign of maturation
of neural systems in the brain (Steen et al., 2005). More likely, the
decreasing levels reﬂect different aspects of neural system integrity
and energy. However, there have been reports on increased creatine
and choline levels with age in healthy subjects and increased Gln/Glu
ratios and choline levels in schizophrenia patients (Bustillo et al.,
2014; Maudsley et al., 2009). Thus, overall there were signiﬁcant
lower levels of all metabolites with older age, particularly in the pre-
frontal and not in the parieto-occipital cortex, with the exception of
GABAwhich had lower levels in the parieto-occipital but not prefrontal
cortex with increasing age.We found no signiﬁcant differences in the
extent of decline with age in patients with schizophrenia as com-
pared to controls, although some levels (NAA) did seem to decline
disproportionally in the patients.
Irrespective of disease, signiﬁcant differences between the sexes
were found in prefrontal glutamate and parieto-occipital NAA levels,
with males having lower levels as compared to females. We did not
ﬁnd any differential ﬁndings for males and females in patients as com-
pared to controls. Thus, GABA/Cr differences between patients and con-
trols could not be explained by differences between the sexes.
Although there were no signiﬁcant associations found between
medication use and metabolite levels, a limitation of this study is the
lack of control for medication use during the lifespan. Also, this study
has a rather small sample size. Substance use, in particular smoking
(Gallinat et al., 2007), has been found to affect neurometabolite levels.
Therefore, in a post-hoc analysis we added smoking, alcohol and canna-
bis intake as a covariate. Smoking, alcohol and cannabis intake did not
alter the ﬁndings. In vivoMRS measurements have some limitations to
take into account. One, withMRS one cannot distinguish between intra-
cellular and extracellularmetabolite levels. Two, because of its low con-
centration a large voxel size is needed to reliably and time-efﬁciently
measure GABA. Hence the voxel contained both gray and white matter.
However, the gray and white matter fractions in the individual voxels
were controlled for in the analysesmaking a large inﬂuence on the ﬁnd-
ings unlikely. The ﬁndings did not alter considerably when leaving out
the corrections for gray and white matter fractions from the analyses.
Three, the creatine peak that is derived from the MEGA-sLASER se-
quence to calculate the GABA/Cr ratio, contains contributions of GABA
and macromolecules that were not accounted for since it is difﬁcult to
determine the relative contribution of macromolecules. However, the
contributions of GABA andmacromolecules to the creatine peak are rel-
atively small. Unlike the water signal, the creatine signal is obtained at
exactly the same time as the GABA signal, so in the presence of subtle
instability artifacts. Also, because of the long TE in theMEGA-sLASER se-
quence, the water signal is partially decayed due to T2 relaxation. The
creatine signal is also partially decayed due to T2 relaxation, but this ef-
fect is smaller compared to the effect T2 relaxation has on thewater sig-
nal. Moreover, the T2 relaxation of water differs between white matter,
graymatter and CSF, thus it ismore difﬁcult to calculate a correction fac-
tor because fractions of white matter, graymatter and CSF differ among
individuals. For the data to be as accurate as possible, creatine was used
as a reference instead of water. Although there were no differences in
creatine levels found between patients and healthy controls in this
study, one study does report changes in creatine levels in schizophrenia
(Ongür et al., 2009).
Despite the use of the sensitivity optimized sLASER technique, in
some of the spectra glutamine and NAAG, which are important compo-
nents in glutamatergic metabolism, could not be assessed accurately.
While the relatively short scan time could have been increased to im-
prove SNR, our current study shows that in 9% of the spectra the CRLB
for glutaminewas above 20% and 53% theCRLB forNAAGwas above 20%.
406 A. Marsman et al. / NeuroImage: Clinical 6 (2014) 398–407In conclusion, using 1H-MRS at 7 T, prefrontal GABA/Cr ratios appear
to be decreased in medicated patients with schizophrenia as compared
to healthy controls, in contrast to previously reported elevations in un-
medicated patients. Moreover, GABA/Cr ratios are associated with the
level of cognitive functioning, with high functioning patients having
lower GABA/Cr ratios. This suggests a role for GABA in the earlier
stages of the disease in schizophrenia, and replication studies are
needed to assess the effects of antipsychotic medication use, aging,
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